These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 22894676

  • 1. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
    Imarisio I, Paglino C, Ganini C, Magnani L, Caccialanza R, Porta C.
    Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
    [Abstract] [Full Text] [Related]

  • 2. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Rosmorduc O, Chevreau C, Dielenseger P, Ederhy S, Goldwasser F, Grange JD, Mortier L, Neidhardt-Berard ME, Robert C, Scotté F, Seitz JF.
    Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM, Plowman PN, Reznek R, Ball SA.
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract] [Full Text] [Related]

  • 7. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.
    Clin Cancer Res; 2007 Mar 15; 13(6):1801-9. PubMed ID: 17363536
    [Abstract] [Full Text] [Related]

  • 8. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B.
    Ann Oncol; 2011 Aug 15; 22(8):1812-23. PubMed ID: 21324953
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C, Müezzinoğlu T, Ermertcan AT, Kayhan TC, Temeltaş G, Oztürkcan S, Temiz P.
    Cutan Ocul Toxicol; 2009 Aug 15; 28(2):90-2. PubMed ID: 19514932
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, Moreno JM, Forner A, Varela M.
    Gastroenterol Hepatol; 2010 Dec 15; 33(10):741-52. PubMed ID: 20851505
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sorafenib-induced palmoplantar hyperkeratosis.
    Lountzis NI, Maroon MS.
    J Drugs Dermatol; 2008 Jun 15; 7(6):588-9. PubMed ID: 18561593
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.